Companies › Invivyd
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 1; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VYD2311 Monoclonal antibody targeting SARS-CoV-2 spike protein; blocks viral entry into cells | – | Phase 3 | COVID-19 | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06523153 | VYD2311 | Phase 1 | COVID-19 | Infectious disease | May 2025 |
| NCT07298434 | VYD2311 | Phase 3 | COVID-19 | Infectious disease | Aug 2026 |
| NCT07655180 | VYD2311 | Phase 3 | COVID-19 | Infectious disease | Aug 2026 |
Cash of $160m on 2026-06-30; operating cash outflow about $172m a year; runway about 11 months at that burn, to Jun 2027
Press releases filed as 8-K in the last year:
No annotated target.
–
Verrica Pharmaceuticals TCM Biotech International Vivacelle Bio Ansun Biopharma SymBio Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.